Immunic, Inc. (NASDAQ:IMUX) Short Interest Up 10.3% in November

Immunic, Inc. (NASDAQ:IMUX - Get Free Report) was the target of a significant increase in short interest in the month of November. As of November 30th, there was short interest totalling 4,190,000 shares, an increase of 10.3% from the November 15th total of 3,800,000 shares. Based on an average trading volume of 885,100 shares, the days-to-cover ratio is currently 4.7 days.

Analysts Set New Price Targets

A number of equities analysts recently weighed in on the stock. HC Wainwright started coverage on shares of Immunic in a research report on Monday, November 25th. They set a "buy" rating and a $10.00 target price for the company. StockNews.com downgraded shares of Immunic from a "hold" rating to a "sell" rating in a report on Monday, November 11th. B. Riley initiated coverage on Immunic in a report on Tuesday, August 27th. They issued a "buy" rating and a $6.00 target price on the stock. EF Hutton Acquisition Co. I upgraded Immunic to a "strong-buy" rating in a research report on Monday, September 16th. Finally, Leerink Partnrs upgraded Immunic to a "strong-buy" rating in a report on Monday, September 9th. One analyst has rated the stock with a sell rating, five have given a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of "Buy" and an average price target of $11.80.

Insider Buying and Selling at Immunic

In other Immunic news, Director Richard Alan Rudick purchased 87,300 shares of the company's stock in a transaction on Tuesday, November 12th. The stock was acquired at an average cost of $1.15 per share, for a total transaction of $100,395.00. Following the purchase, the director now directly owns 87,300 shares of the company's stock, valued at $100,395. This trade represents a ∞ increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Insiders own 3.00% of the company's stock.

Hedge Funds Weigh In On Immunic

Large investors have recently modified their holdings of the stock. Vanguard Group Inc. lifted its stake in Immunic by 100.7% in the first quarter. Vanguard Group Inc. now owns 3,394,047 shares of the company's stock worth $4,480,000 after purchasing an additional 1,703,047 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. lifted its stake in shares of Immunic by 70.8% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 102,257 shares of the company's stock worth $169,000 after acquiring an additional 42,383 shares during the last quarter. Jane Street Group LLC boosted its holdings in Immunic by 121.4% during the 3rd quarter. Jane Street Group LLC now owns 70,299 shares of the company's stock valued at $116,000 after acquiring an additional 38,553 shares during the period. Virtu Financial LLC bought a new position in Immunic in the 3rd quarter valued at $50,000. Finally, State Street Corp increased its stake in Immunic by 7.5% in the third quarter. State Street Corp now owns 167,145 shares of the company's stock worth $276,000 after purchasing an additional 11,642 shares during the period. Institutional investors own 51.82% of the company's stock.

Immunic Stock Performance

NASDAQ IMUX remained flat at $1.13 during trading hours on Friday. The company's stock had a trading volume of 424,112 shares, compared to its average volume of 755,572. The stock has a market capitalization of $101.79 million, a PE ratio of -0.92 and a beta of 1.89. Immunic has a 52 week low of $0.97 and a 52 week high of $2.11. The stock has a 50 day moving average price of $1.28 and a 200-day moving average price of $1.34.

Immunic Company Profile

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.